Peptides · Peptide comparison
Lactoferricin B vs LL-37
A 25-amino-acid antimicrobial peptide fragment derived from bovine lactoferrin by pepsin cleavage, featuring a twisted antiparallel beta-sheet structure with broad-spectrum bactericidal activity, anti-biofilm properties, and emerging anticancer potential through selective membrane disruption mediated by the critical RRWQWR motif
Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers
- Immune
- Immune
At a glance
Quick comparison
Efficacy
Benefit ratings
Fighting Germs
Cancer Cell Targeting
Immune Support
Wound Healing
Fighting Infections
Immune Boost
Technical data
Compound specifications
Lactoferricin B
- Molecular formula
- Approximately C142H224N46O34S2 (varies slightly by reported sequence)
- Molecular weight
- ~3,126 Da (25-amino-acid bovine lactoferricin B)
- Half-life
- Plasma half-life: minutes (proteolytic degradation); gastrointestinal persistence: hours (relative resistance to trypsin and chymotrypsin compared to unstructured peptides); beta-sheet structure and disulfide bond provide moderate protease resistance
- Bioavailability
- Generated endogenously during gastric digestion of dietary lactoferrin; partially resistant to further proteolytic degradation due to beta-sheet structure and disulfide bond; systemic bioavailability limited by intestinal proteases and hepatic metabolism
- CAS number
- 146897-68-9
LL-37
- Molecular formula
- C205H340N60O53
- Molecular weight
- 4,493.26 Da
- Half-life
- Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
- Bioavailability
- Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery
- CAS number
- 154947-66-7
Protocols
Dosing compared
Lactoferricin B
No dose levels recorded.
LL-37
Topical
- 0.5 mg/mL gelTwice weekly · 4 weeksLowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].
- 1.6 mg/mL gelTwice weekly · 4 weeksMid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].
Applications
Best suited for
Lactoferricin B
- Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
- Lactoferricin B is particularly well-suited for individuals focused on research into dairy-derived antimicrobial peptides and natural innate defense mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
- Lactoferricin B is particularly well-suited for individuals focused on investigation of structure-activity relationships in beta-sheet antimicrobial peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
- Lactoferricin B is particularly well-suited for individuals focused on preclinical development of anticancer peptides targeting membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion
- Lactoferricin B is particularly well-suited for individuals focused on understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
LL-37
- Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
- LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
- Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
- LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3][5].
- Anti-biofilm strategies for chronic wound infections and medical device-associated infections
- LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
- Boosting innate immune defense in immunocompromised or aging individuals
- LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2].
Safety profile
Side effects
Lactoferricin B
Common
- Mild GI discomfort
- Bitter taste
- Local irritation (topical use)
- Mild flatulence
Uncommon
- Allergic reaction in milk-sensitive individuals
Serious
- Hemolytic activity at high concentrations
LL-37
Common
- Local site irritation
- Transient stinging or burning
- Mild perilesional erythema
- Increased wound exudate
Uncommon
- Allergic contact reaction
Serious
- Hemolytic activity at systemic concentrations
Research status
Safety & evidence
Lactoferricin B
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Lactoferricin B is a 25-amino acid peptide fragment of bovine lactoferrin, a protein found in cow's milk [2]. Preclinical studies show excellent tolerability with no hepatotoxicity, nephrotoxicity, or genotoxicity in animal models even at supraphysiological doses. The antimicrobial and antifungal mechanism (iron sequestration and membrane disruption) appears selective for pathogenic microorganisms with minimal effect on commensal bacteria at therapeutic concentrations.
Contraindications
- Known allergy to bovine milk proteins or lactoferrin — cross-reactivity possible
- Pregnancy and breastfeeding — insufficient safety data for therapeutic-dose lactoferricin supplementation
- Active hemolytic conditions — at higher concentrations lactoferricin shows some hemolytic activity that may worsen hemolysis
- Iron overload conditions (hemochromatosis) — lactoferricin retains some iron-binding capacity from the parent lactoferrin molecule
LL-37
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, [2] conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.
Contraindications
- Known hypersensitivity to cathelicidin peptides or formulation components
- Active hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
- Pregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
- Severe renal impairment — peptide clearance may be altered
Decision guide
Which is right for you?
Lactoferricin B
Choose Lactoferricin B if…
- Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
- Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
- Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
- Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion
LL-37
Choose LL-37 if…
- Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
- Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
- Anti-biofilm strategies for chronic wound infections and medical device-associated infections
- Boosting innate immune defense in immunocompromised or aging individuals